Small molecule · developed by Kiora Pharmaceuticals
KIO-101 is a small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), an enzyme in the de novo pyrimidine biosynthesis pathway. It is studied in dry eye disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05629364 | Phase 2 | Dry Eye Disease | Terminated | KPRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Dry Eye Disease
See KPRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KPRX catalysts and pipeline →